|Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.|
|PMID: 17243069 Owner: NLM Status: MEDLINE|
|BACKGROUND: We evaluated the efficacy and safety of oral posaconazole for human immunodeficiency virus (HIV)-infected subjects with oropharyngeal candidiasis (OPC) and/or esophageal candidiasis (EC) who were clinically refractory to treatment with oral fluconazole or itraconazole.
METHODS: Subjects with confirmed OPC or EC who did not improve after receiving standard courses of fluconazole or itraconazole treatment were eligible for study enrollment. Subjects received either oral posaconazole (400 mg twice daily) for 3 days followed by oral posaconazole (400 mg once daily) for 25 days (regimen A; 103 patients) or oral posaconazole (400 mg twice daily) for 28 days (regimen B; 96 patients). The primary end point was cure or improvement after 28 days. Primary efficacy analyses were performed on the subset of treated subjects with refractory disease (e.g., baseline culture positive for fluconazole- or itraconazole-resistant Candida species or persistent or progressive clinical signs or symptoms consistent with treatment failure).
RESULTS: Of the modified intent-to-treat population, 132 (75%) of 176 subjects achieved a clinical response to posaconazole treatment. Clinical response rates were similar between regimen A recipients (75.3%) and regimen B recipients (74.7%). Clinical responses occurred in 67 (73%) of 92 subjects with baseline isolates resistant to fluconazole, 49 (74%) of 66 subjects with baseline isolates resistant to itraconazole, and 42 (74%) of 57 subjects with isolates resistant to both. Clinical response was achieved in 32 (74.4%) of 43 subjects with endoscopically documented EC. The most common treatment-related adverse events were diarrhea (11%), neutropenia (7%), flatulence (6%), and nausea (6%). Eight subjects (4%) discontinued therapy as a result of a treatment-related adverse event.
CONCLUSIONS: Posaconazole offers a safe and effective treatment option for HIV-infected subjects with azole-refractory OPC and/or EC.
|Daniel J Skiest; Jose A Vazquez; Gregory M Anstead; John R Graybill; Jacques Reynes; Douglas Ward; Roberta Hare; Navdeep Boparai; Randi Isaacs|
Related Documents :
|19160539 - Onychomycosis caused by fusarium sp in sri lanka: prevalence, clinical features and res...
19644189 - Evaluation of safety and efficacy of prolonged suppressive therapy of genital herpes wi...
10524579 - How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
16562709 - Representative drug susceptibility patterns for guiding design of retreatment regimens ...
9240009 - Itraconazole for treatment of oral candidosis in pediatric cancer patients.
11413929 - One week pulse therapy with itraconazole (200 mg day-1) for onychomycosis. evaluation o...
15106019 - Incidence of arrhythmic events in patients with implantable cardioverter-defibrillator ...
23331199 - Hartmann colostomy with ligasure.
25228649 - Effect of cilostazol following endovascular intervention for peripheral artery disease.
|Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2007-01-17|
|Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Volume: 44 ISSN: 1537-6591 ISO Abbreviation: Clin. Infect. Dis. Publication Date: 2007 Feb|
|Created Date: 2007-01-23 Completed Date: 2007-02-28 Revised Date: 2013-11-25|
Medline Journal Info:
|Nlm Unique ID: 9203213 Medline TA: Clin Infect Dis Country: United States|
|Languages: eng Pagination: 607-14 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
AIDS-Related Opportunistic Infections
Candidiasis / diagnosis, drug therapy*
Candidiasis, Oral / diagnosis, drug therapy
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Fungal
Esophageal Diseases / diagnosis, drug therapy
Fluconazole / administration & dosage, adverse effects
Itraconazole / administration & dosage, adverse effects
Severity of Illness Index
Triazoles / administration & dosage*, adverse effects
|0/Triazoles; 304NUG5GF4/Itraconazole; 6TK1G07BHZ/posaconazole; 8VZV102JFY/Fluconazole|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hospitalization and mortality among HIV-infected children after receiving highly active antiretrovir...
Next Document: The effect of spatial and temporal heterogeneity on the design and analysis of empirical studies of ...